Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fulcrum Pharma appoints new CEO
Most recently, Dr Armstrong was president and CEO of CuraGen, from March 2006 until September 2007. Prior to CuraGen, Mr Armstrong was CEO of Bioaccelerate Holdings, Provensis and
Most recently, Dr Armstrong was president and CEO of CuraGen, from March 2006 until September 2007. Prior to CuraGen, Mr Armstrong was CEO of Bioaccelerate Holdings, Provensis and
Through the partnership, Medical Expert will become a distributor of Sectra’s medical systems in Japan. Initially, the agreement involves Sectra PACS (system for handling radiology images) and Sectra’s
Under the terms of the agreement, Euromed will have exclusive marketing, sales and distribution rights in Austria, Germany and Switzerland for InnerCool’s portfolio of temperature modulation systems. This
The data continues to show an increase in the number of patients responding with increasing duration of response in chronic and accelerated phase patients. To date 34 patients
The distributor agreement covers WaferGen’s entire family of SmartSlide Micro-Incubation System products. Alnoor Shivji, WaferGen’s chairman and CEO, said: “With the signing of this agreement, company has established
The Everest trial is evaluating the safety and efficacy of the MitraClip device for the treatment of mitral regurgitation (MR). The data analysis was based on 23 patients
Under the terms of the agreement, Cardinal Health will be the primary distributor for ClearCount’s patented SmartSponge system to hospitals, surgery centers and other health care distributors in
In addition, in a post-hoc analysis, treatment with rolofylline was associated with a trend towards reduced 60-day mortality or hospital readmission for cardiovascular or renal causes. Rolofylline increases
Under the special protocol assessment (SPA), the company and the FDA have agreed to design features for the pivotal Phase III efficacy studies including the primary endpoints, the
BioDelivery Sciences has received a $2.5 million milestone payment for completion of the clinical trial work supporting the dossier and expects to receive an additional milestone payment on